Cost-Effectiveness and Budget Impact Models: Building for Scrutiny, Not Just Submission

An economic model is an argument expressed in numbers. Payers rarely reject the arithmetic; they reject the assumptions, and the assumptions they cannot see are the ones they trust least.

Two models, two questions

A cost-effectiveness model asks whether the health gained justifies the extra cost, usually over a long horizon. A budget impact model asks what the health system will actually spend, year by year, over a short horizon of a few years. Payers often care more about the second, because it is the one that hits a budget line. The two should share inputs and be consistent with each other.

Structure follows the disease

  • Markov or state-transition models suit chronic conditions with defined health states.
  • Partitioned survival models are widely used in oncology, built directly on survival curves.
  • Decision trees and microsimulation suit acute episodes or heterogeneous patients.

The structure should reflect the clinical pathway and be no more complicated than the decision requires.

Where scrutiny concentrates

  • Extrapolation: projecting beyond trial follow-up is often the largest driver of results. Justify the curve choice, show alternatives and test them.
  • Treatment effect duration: assuming benefits persist indefinitely draws challenge.
  • Utilities and costs: sources, local relevance and consistency across the model.
  • Uptake and market share: optimistic assumptions undermine budget impact credibility quickly.
  • Comparators and subsequent therapy: must reflect real local practice.

Show the uncertainty

Probabilistic and deterministic sensitivity analyses, scenario analyses and a clear list of key assumptions are expected. Reporting in line with recognised standards such as the CHEERS checklist helps reviewers follow what you did. Validation matters too: checks of internal logic, comparison against trial results, and where possible external validation.

Make it adaptable and transparent

A model that cannot be adapted to a country’s costs, population and comparators is a model that will be adapted badly. Build in country-specific inputs from the start, document every source and give reviewers a clear route to understand how results are produced. Many HTA bodies request an accessible version of the model, so assume yours will be opened and tested.

A short checklist

  • Does the model structure match the clinical pathway in each target market?
  • Are the key drivers identified and tested in scenario analyses?
  • Do the cost-effectiveness and budget impact models share consistent inputs?
  • Could an outside reviewer rebuild the results from the documentation alone?

A model that passes these checks is also easier to update when new data or new comparators appear.

How PQRA helps

PQRA does not build economic models, which belong with specialist HEOR teams. We help sponsors align regulatory assumptions, such as indication wording, population and posology, with what the model assumes, so that the economic case does not drift away from the licence.

Ready to discuss your market access plan? Contact PQRA to talk through your product and your target markets.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *